旭輝控股集團(00884.HK)擬發行2億美元綠色優先票據
格隆匯7月28日丨旭輝控股集團(00884.HK)公告,擬發行2025年到期為2億美元的5.95%額外綠色優先票據。
於2020年7月29日,公司及附屬公司擔保人就額外票據發行與高盛(亞洲)有限責任公司訂立購買協議。經扣除有關額外票據發行的包銷折扣及應付佣金後,額外票據發行的估計所得款項淨額將約為2.006億美元,而公司擬將額外票據發行所得款項淨額用於其現有債務再融資。
公司或會因應不斷變化的市況調整其計劃,並因此重新分配所得款項淨額用途。公司將尋求該等額外票據於聯交所上市。該等額外票據獲納入聯交所不應被視為公司或該等額外票據的利好指標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.